Cross Country Healthcare Earnings Call Transcripts
Fiscal Year 2025
-
Revenue and profitability declined in 2025 due to merger-related disruptions, but momentum has improved with a strong balance sheet, technology investments, and cost reductions. Sequential growth is expected throughout 2026, with a return to year-over-year growth by Q3 or Q4.
Fiscal Year 2024
-
Q3 revenue and adjusted EBITDA met guidance, with strong performance in home care, physician staffing, and education offsetting travel nurse and allied softness. Gross margin remains pressured by competition, but diversification and technology investments support long-term growth.
-
Q2 revenue and adjusted EBITDA were near the high end of guidance, with travel demand rebounding and strong performance in locums, home care, and education. Margin pressures persist, but technology investments and cost actions support long-term growth. Sequential revenue growth is expected in Q4.
-
Temp staffing demand has stabilized but remains below pre-pandemic levels, with hospitals reducing contingent labor and exploring new staffing models. Growth is driven by technology adoption, robust pipelines in vendor-neutral agreements, and expansion in locums and education, while financial discipline and margin improvement remain key priorities.
-
The conference highlighted persistent nurse shortages, ongoing demand stabilization, and the company's tech-driven approach to workforce management. Investments in AI-powered platforms like Xperience and Intellify are expanding market reach and driving high-margin growth opportunities.